{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:39:20Z","timestamp":1792471160932,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-026-07523-z","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:06:29Z","timestamp":1792461989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of 131I-MIBG dose escalation (12 vs. 18\u00a0mCi\/kg) during conditioning for autologous hematopoietic stem cell transplantation in pediatric neuroblastoma: a retrospective cohort study"],"prefix":"10.1007","volume":"185","author":[{"given":"Amirali","family":"Kalantari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Behfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Karimizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atieh","family":"Karimzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Paymani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Farzanehfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrshad","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arghavan","family":"Tajalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooya","family":"Ashkevari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashin","family":"Mohseni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najibe","family":"Karami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8935-079X","authenticated-orcid":false,"given":"Amir Ali","family":"Hamidieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"7523_CR1","volume-title":"Nelson textbook of pediatrics","author":"R Kliegman","year":"2024","unstructured":"Kliegman R, Blum NJ, Tasker RC, Wilson KM, St. Geme JW, Schuh AM (2024) Nelson textbook of pediatrics, Edition 22. Elsevier, Philadelphia, PA","edition":"Edition 22"},{"key":"7523_CR2","first-page":"1","volume":"42","author":"SG DuBois","year":"2022","unstructured":"DuBois SG, Macy ME, Henderson TO (2022) High-risk and relapsed neuroblastoma: toward more cures and better outcomes. Am Soc Clin Oncol Educ Book 42:1\u201313","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"7523_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00441-018-2821-2","volume":"372","author":"VP Tolbert","year":"2018","unstructured":"Tolbert VP, Matthay KK (2018) Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res 372(2):195\u2013209","journal-title":"Cell Tissue Res"},{"issue":"23","key":"7523_CR4","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMra0804577","volume":"362","author":"JM Maris","year":"2010","unstructured":"Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362(23):2202\u20132211","journal-title":"N Engl J Med"},{"issue":"12","key":"7523_CR5","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1007\/s00431-022-04617-2","volume":"181","author":"Q Sun","year":"2022","unstructured":"Sun Q, Chen Y, Jin Q, Yuan X (2022) A nomogram for predicting recurrence-free survival of intermediate and high-risk neuroblastoma. Eur J Pediatr 181(12):4135\u20134147","journal-title":"Eur J Pediatr"},{"issue":"4","key":"7523_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ejca.2013.11.016","volume":"50","author":"JS Wilson","year":"2014","unstructured":"Wilson JS, Gains JE, Moroz V, Wheatley K, Gaze MN (2014) A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer 50(4):801\u2013815","journal-title":"Eur J Cancer"},{"issue":"31","key":"7523_CR7","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/JCO.21.00703","volume":"39","author":"SG DuBois","year":"2021","unstructured":"DuBois SG, Granger MM, Groshen S, Tsao-Wei D, Ji L, Shamirian A et al (2021) Randomized phase II trial of MIBG versus MIBG, vincristine, and irinotecan versus MIBG and vorinostat for patients with relapsed or refractory neuroblastoma: a report from NANT Consortium. J Clin Oncol 39(31):3506\u20133514","journal-title":"J Clin Oncol"},{"issue":"5","key":"7523_CR8","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/petr.12271","volume":"18","author":"AA Hamidieh","year":"2014","unstructured":"Hamidieh AA, Beiki D, Paragomi P, Fallahi B, Behfar M, Fard-Esfahani A et al (2014) The potential role of pretransplant MIBG diagnostic scintigraphy in targeted administration of 131I-MIBG accompanied by ASCT for high-risk and relapsed neuroblastoma: a pilot study. Pediatr Transplant 18(5):510\u2013517","journal-title":"Pediatr Transplant"},{"issue":"8","key":"7523_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41571-022-00643-z","volume":"19","author":"B Qiu","year":"2022","unstructured":"Qiu B, Matthay KK (2022) Advancing therapy for neuroblastoma. Nat Rev Clin Oncol 19(8):515\u2013533","journal-title":"Nat Rev Clin Oncol"},{"key":"7523_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010149","author":"T Flaadt","year":"2025","unstructured":"Flaadt T, Rehm J, Simon T, Hero B, Ladenstein RL, Lode HN et al (2025) Long-term outcomes and quality of life of high-risk neuroblastoma patients treated with a multimodal treatment including anti-GD2 immunotherapy: a retrospective cohort study. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17010149","journal-title":"Cancers (Basel)"},{"key":"7523_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17111812","author":"V Andrade-Perez","year":"2025","unstructured":"Andrade-Perez V, Raynal NJ (2025) Interplay between the epigenome, the microenvironment, and the immune system in neuroblastoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17111812","journal-title":"Cancers (Basel)"},{"key":"7523_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2019.09.025","volume":"124","author":"ML Tas","year":"1990","unstructured":"Tas ML, Reedijk AMJ, Karim-Kos HE, Kremer LCM, van de Ven CP, Dierselhuis MP et al (1990) Neuroblastoma between 1990 and 2014 in the Netherlands: increased incidence and improved survival of high-risk neuroblastoma. Eur J Cancer 124:47\u201355","journal-title":"Eur J Cancer"},{"key":"7523_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194941","author":"ML Tas","year":"2021","unstructured":"Tas ML, Dootjes LW, Fiocco M, de Krijger RR, Dierselhuis MP, van Eijkelenburg NKA et al (2021) Anti-GD2 based immunotherapy prevents late events in high-risk neuroblastoma patients over 18 months at diagnosis. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13194941","journal-title":"Cancers (Basel)"},{"issue":"4","key":"7523_CR14","volume":"4","author":"F Peinemann","year":"2019","unstructured":"Peinemann F, van Dalen EC, Enk H, Tytgat GA (2019) Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. Cochrane Database Syst Rev 4(4):Cd012442","journal-title":"Cochrane Database Syst Rev"},{"issue":"35","key":"7523_CR15","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.21.02478","volume":"40","author":"AV Desai","year":"2022","unstructured":"Desai AV, Gilman AL, Ozkaynak MF, Naranjo A, London WB, Tenney SC et al (2022) Outcomes following GD2-directed postconsolidation therapy for neuroblastoma after cessation of random assignment on ANBL0032: a report from the Children\u2019s Oncology Group. J Clin Oncol 40(35):4107\u20134118","journal-title":"J Clin Oncol"},{"issue":"4","key":"7523_CR16","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s10555-024-10212-8","volume":"43","author":"M Rados","year":"2024","unstructured":"Rados M, Landegger A, Schmutzler L, Rabidou K, Taschner-Mandl S, Fetahu IS (2024) Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives. Cancer Metastasis Rev 43(4):1401\u20131417","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"7523_CR17","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41591-025-03513-0","volume":"31","author":"CH Li","year":"2025","unstructured":"Li CH, Sharma S, Heczey AA, Woods ML, Steffin DHM, Louis CU et al (2025) Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat Med 31(4):1125\u20131129","journal-title":"Nat Med"},{"key":"7523_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02380","volume":"9","author":"RM Richards","year":"2018","unstructured":"Richards RM, Sotillo E, Majzner RG (2018) CAR T cell therapy for neuroblastoma. Front Immunol 9:2380","journal-title":"Front Immunol"},{"key":"7523_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00873","volume":"11","author":"KO McNerney","year":"2020","unstructured":"McNerney KO, Karageorgos SA, Hogarty MD, Bassiri H (2020) Enhancing neuroblastoma immunotherapies by engaging iNKT and NK cells. Front Immunol 11:873","journal-title":"Front Immunol"},{"issue":"1","key":"7523_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-70958-7","volume":"14","author":"R Mohseni","year":"2024","unstructured":"Mohseni R, Mahdavi Sharif P, Behfar M, Shojaei S, Shoae-Hassani A, Jafari L et al (2024) Phase I study of safety and efficacy of allogeneic natural killer cell therapy in relapsed\/refractory neuroblastomas post autologous hematopoietic stem cell transplantation. Sci Rep 14(1):20971","journal-title":"Sci Rep"},{"key":"7523_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2024.104898","volume":"407","author":"A Ghasempour","year":"2025","unstructured":"Ghasempour A, Mohseni R, Sharif PM, Hamidieh AA (2025) Natural killer cell-based therapies in neuroblastoma. Cell Immunol 407:104898","journal-title":"Cell Immunol"},{"key":"7523_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105577","author":"R Mohseni","year":"2026","unstructured":"Mohseni R, Kalantari A, Behfar M, Karimizadeh Z, Khalilzadeh F, Eftekhar A et al (2026) TIL therapy in relapsed\/refractory neuroblastoma: a translational roadmap from immunobiology to early-phase trials. Crit Rev Oncol Hematol. https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105577","journal-title":"Crit Rev Oncol Hematol"},{"key":"7523_CR23","volume-title":"Nathan and Oski\u2019s hematology and oncology of infancy and childhood","author":"SH Orkin","year":"2015","unstructured":"Orkin SH, Fisher DE, Ginsburg D, Look AT, Lux SE, Nathan DG (2015) Nathan and Oski\u2019s hematology and oncology of infancy and childhood. Elsevier\/Saunders, Philadelphia, PA"},{"issue":"11","key":"7523_CR24","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/pbc.25580","volume":"62","author":"KC Kraal","year":"2015","unstructured":"Kraal KC, Tytgat GA, van Eck-Smit BL, Kam B, Caron HN, van Noesel M (2015) Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan. Pediatr Blood Cancer 62(11):1886\u20131891","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"7523_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s13139-018-0523-z","volume":"52","author":"D Kayano","year":"2018","unstructured":"Kayano D, Kinuya S (2018) Current consensus on I-131 MIBG therapy. Nucl Med Mol Imaging 52(4):254\u2013265","journal-title":"Nucl Med Mol Imaging"},{"issue":"5","key":"7523_CR26","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/pbc.24351","volume":"60","author":"S French","year":"2013","unstructured":"French S, DuBois SG, Horn B, Granger M, Hawkins R, Pass A et al (2013) 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. Pediatr Blood Cancer 60(5):879\u201384","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"7523_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29117","volume":"68","author":"BD Weiss","year":"2021","unstructured":"Weiss BD, Yanik G, Naranjo A, Zhang FF, Fitzgerald W, Shulkin BL et al (2021) A safety and feasibility trial of (131) I-MIBG in newly diagnosed high-risk neuroblastoma: a Children\u2019s Oncology Group study. Pediatr Blood Cancer 68(10):e29117","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"7523_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28775","volume":"68","author":"S Giardino","year":"2021","unstructured":"Giardino S, Piccardo A, Conte M, Puntoni M, Bertelli E, Sorrentino S et al (2021) (131) I-Meta-iodobenzylguanidine followed by busulfan and melphalan and autologous stem cell rescue in high-risk neuroblastoma. Pediatr Blood Cancer 68(2):e28775","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"7523_CR29","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1007\/s00259-021-05630-7","volume":"49","author":"R Kuroda","year":"2022","unstructured":"Kuroda R, Wakabayashi H, Araki R, Inaki A, Nishimura R, Ikawa Y et al (2022) Phase I\/II clinical trial of high-dose [(131)I] meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding single myeloablative chemotherapy and haematopoietic stem cell transplantation. Eur J Nucl Med Mol Imaging 49(5):1574\u20131583","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"7523_CR30","doi-asserted-by":"publisher","first-page":"S251","DOI":"10.1016\/j.bbmt.2011.12.138","volume":"18","author":"AA Hamidieh","year":"2012","unstructured":"Hamidieh AA, Beigi D, Fallahi B, Behfar M, Jalili M, Hamdi A et al (2012) Comparison of autologous hematopoietic stem cell transplantation with and without metaiodobenzylguanidine (MIBG) in patients with high risk neuroblastoma. Biol Blood Marrow Transplant 18(2):S251","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"7523_CR31","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00259-002-0973-4","volume":"29","author":"M Monsieurs","year":"2002","unstructured":"Monsieurs M, Brans B, Bacher K, Dierckx R, Thierens H (2002) Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans. Eur J Nucl Med Mol Imaging 29(12):1581\u20131587","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"7523_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/BF02285457","volume":"18","author":"SL Fielding","year":"1991","unstructured":"Fielding SL, Flower MA, Ackery D, Kemshead JT, Lashford LS, Lewis I (1991) Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med 18(5):308\u2013316","journal-title":"Eur J Nucl Med"},{"issue":"9","key":"7523_CR33","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.2967\/jnumed.109.064469","volume":"50","author":"SE Buckley","year":"2009","unstructured":"Buckley SE, Chittenden SJ, Saran FH, Meller ST, Flux GD (2009) Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med 50(9):1518\u20131524","journal-title":"J Nucl Med"},{"issue":"4","key":"7523_CR34","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/00006231-200104000-00004","volume":"22","author":"MA Monsieurs","year":"2001","unstructured":"Monsieurs MA, Thierens HM, Vral A, Brans B, De Ridder L, Dierckx RA (2001) Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours. Nucl Med Commun 22(4):367\u201374","journal-title":"Nucl Med Commun"},{"issue":"10","key":"7523_CR35","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1088\/0031-9155\/41\/10\/006","volume":"41","author":"MA Flower","year":"1996","unstructured":"Flower MA, Fielding SL (1996) Radiation dosimetry for 131I-mIBG therapy of neuroblastoma. Phys Med Biol 41(10):1933\u20131940","journal-title":"Phys Med Biol"},{"issue":"5","key":"7523_CR36","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00259-008-0715-3","volume":"35","author":"F Giammarile","year":"2008","unstructured":"Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (2008) EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 35(5):1039\u20131047","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7523_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-95564-3","volume-title":"Nuclear medicine textbook : methodology and clinical applications","author":"D Volterrani","year":"2019","unstructured":"Volterrani D, Erba PA, Carri\u00f3 I, Strauss HW, Mariani G (2019) Nuclear medicine textbook\u202f: methodology and clinical applications. Springer International Publishing\u202f: Imprint: Springer, Cham"},{"issue":"2","key":"7523_CR38","first-page":"195","volume":"20","author":"MN Gaze","year":"2005","unstructured":"Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST (2005) Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 20(2):195\u2013199","journal-title":"Cancer Biother Radiopharm"},{"issue":"7","key":"7523_CR39","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1118\/1.4921807","volume":"42","author":"P M\u00ednguez","year":"2015","unstructured":"M\u00ednguez P, Flux G, Genoll\u00e1 J, Guayambuco S, Delgado A, Fombellida JC et al (2015) Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with (131)I-metaiodobenzylguanidine with implications for the activity to administer. Med Phys 42(7):3969\u20133978","journal-title":"Med Phys"},{"issue":"5","key":"7523_CR40","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/MNM.0000000000000470","volume":"37","author":"SL George","year":"2016","unstructured":"George SL, Falzone N, Chittenden S, Kirk SJ, Lancaster D, Vaidya SJ et al (2016) Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma. Nucl Med Commun 37(5):466\u2013472","journal-title":"Nucl Med Commun"},{"issue":"2","key":"7523_CR41","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s11307-014-0783-7","volume":"17","author":"SY Huang","year":"2015","unstructured":"Huang SY, Bolch WE, Lee C, Van Brocklin HF, Pampaloni MH, Hawkins RA et al (2015) Patient-specific dosimetry using pretherapy [124I]m-iodobenzylguanidine ([124I]mIBG) dynamic PET\/CT imaging before [131I]mIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol 17(2):284\u201394","journal-title":"Mol Imaging Biol"},{"issue":"7","key":"7523_CR42","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2967\/jnumed.111.098624","volume":"53","author":"KK Matthay","year":"2012","unstructured":"Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG et al (2012) Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. J Nucl Med 53(7):1155\u20131163","journal-title":"J Nucl Med"},{"issue":"4","key":"7523_CR43","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/bjc.2015.12","volume":"112","author":"SG DuBois","year":"2015","unstructured":"DuBois SG, Allen S, Bent M, Hilton JF, Hollinger F, Hawkins R et al (2015) Phase I\/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. Br J Cancer 112(4):644\u2013649","journal-title":"Br J Cancer"},{"issue":"3","key":"7523_CR44","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/JCO.2005.03.6400","volume":"24","author":"KK Matthay","year":"2006","unstructured":"Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B et al (2006) Phase I dose escalation of iodine-131\u2013metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a New Approaches to Neuroblastoma Therapy Consortium study. J Clin Oncol 24(3):500\u2013506","journal-title":"J Clin Oncol"},{"key":"7523_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.647361","volume":"11","author":"M Ussowicz","year":"2021","unstructured":"Ussowicz M, Wieczorek A, D\u0142u\u017cniewska A, Pieczonka A, D\u0119bski R, Drabko K et al (2021) Factors modifying outcome after MIBG therapy in children with neuroblastoma-a national retrospective study. Front Oncol 11:647361","journal-title":"Front Oncol"},{"issue":"10","key":"7523_CR46","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1158\/1078-0432.CCR-11-1939","volume":"18","author":"KK Matthay","year":"2012","unstructured":"Matthay KK, George RE, Yu AL (2012) Promising therapeutic targets in neuroblastoma. Clin Cancer Res 18(10):2740\u20132753","journal-title":"Clin Cancer Res"},{"key":"7523_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115802","volume":"216","author":"S Mastrangelo","year":"2023","unstructured":"Mastrangelo S, Romano A, Attin\u00e0 G, Maurizi P, Ruggiero A (2023) Timing and chemotherapy association for 131-I-MIBG treatment in high-risk neuroblastoma. Biochem Pharmacol 216:115802","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"7523_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13658","volume":"24","author":"JK Suh","year":"2020","unstructured":"Suh JK, Koh KN, Min SY, Kim YS, Kim H, Im HJ et al (2020) Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with (131) I-MIBG therapy for high-risk neuroblastoma. Pediatr Transplant 24(2):e13658","journal-title":"Pediatr Transplant"},{"issue":"4","key":"7523_CR49","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/21678707.2017.1304212","volume":"5","author":"MA Applebaum","year":"2017","unstructured":"Applebaum MA, Desai AV, Glade Bender JL, Cohn SL (2017) Emerging and investigational therapies for neuroblastoma. Expert Opin Orphan Drugs 5(4):355\u2013368","journal-title":"Expert Opin Orphan Drugs"},{"issue":"22","key":"7523_CR50","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/JCO-24-02612","volume":"43","author":"T Cash","year":"2025","unstructured":"Cash T, Marachelian A, DuBois SG, Chi YY, Baregamyan A, Groshen SG et al (2025) Phase I study of (131)I-metaiodobenzylguanidine with dinutuximab \u00b1 vorinostat for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. J Clin Oncol 43(22):2490\u20132501","journal-title":"J Clin Oncol"},{"issue":"4","key":"7523_CR51","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.bbmt.2014.12.008","volume":"21","author":"GA Yanik","year":"2015","unstructured":"Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A et al (2015) 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant 21(4):673\u2013681","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"7523_CR52","first-page":"1121","volume":"11","author":"A Delgado","year":"2021","unstructured":"Delgado A, Guddati AK (2021) Clinical endpoints in oncology - a primer. Am J Cancer Res 11(4):1121\u20131131","journal-title":"Am J Cancer Res"},{"key":"7523_CR53","unstructured":"Institute NC (n.d.) OS [Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/os.\u00a0Accessed 20 Aug 2026"},{"key":"7523_CR54","unstructured":"Institute NC (n.d.) Event-free survival [Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/event-free-survival. Accessed 20 Aug 2026"},{"key":"7523_CR55","first-page":"432","volume-title":"Gordis epidemiology","author":"DD Celentano","year":"2025","unstructured":"Celentano DD, Szklo M, Farag YMK (2025) Gordis epidemiology, Seventh edition. Elsevier, Philadelphia, PA, p 432","edition":"Seventh edition"},{"key":"7523_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.10.022","author":"Z Hudda","year":"2025","unstructured":"Hudda Z, Webster A, Anderson E, Badia P, Bagatell R, Bhar S et al (2025) Acute toxicities and early outcomes of tandem autologous stem cell transplantation in pediatric high-risk neuroblastoma: a multicenter study. Transplant Cell Ther. https:\/\/doi.org\/10.1016\/j.jtct.2025.10.022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"7523_CR57","doi-asserted-by":"publisher","first-page":"9161","DOI":"10.4081\/ejtm.2020.9161","volume":"30","author":"G Bahoush","year":"2020","unstructured":"Bahoush G, Vafapour M (2020) A case report of severe veno-occlusive disease following autologous stem cell transplantation successfully treated with Defibrotide. Eur J Transl Myol 30(3):9161","journal-title":"Eur J Transl Myol"},{"issue":"12","key":"7523_CR58","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.3324\/haematol.2023.283351","volume":"108","author":"A Sabulski","year":"2023","unstructured":"Sabulski A, Abdullah S, Luebbering N, Aunins B, Castillo C, Lake K et al (2023) Mechanisms of endothelial injury and transplant-associated thrombotic microangiopathy in tandem autologous hematopoietic stem cell transplant for neuroblastoma. Haematologica 108(12):3449\u20133453","journal-title":"Haematologica"},{"key":"7523_CR59","doi-asserted-by":"publisher","first-page":"1064146","DOI":"10.3389\/fendo.2022.1064146","volume":"13","author":"A Cattoni","year":"2022","unstructured":"Cattoni A, Molinari S, Riva B, Di Marco S, Adavastro M, Faraguna MC et al (2022) Thyroid function disorders and secondary cancer following haematopoietic stem cell transplantation in pediatrics: State of the art and practical recommendations for a risk-based follow-up. Front Endocrinol (Lausanne) 13:1064146","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7523_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11040270","author":"A Samim","year":"2021","unstructured":"Samim A, Tytgat GAM, Bleeker G, Wenker STM, Chatalic KLS, Poot AJ et al (2021) Nuclear medicine imaging in neuroblastoma: current status and new developments. J Pers Med. https:\/\/doi.org\/10.3390\/jpm11040270","journal-title":"J Pers Med"},{"issue":"10","key":"7523_CR61","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S1470-2045(13)70309-7","volume":"14","author":"SG Kreissman","year":"2013","unstructured":"Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA et al (2013) Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol 14(10):999\u20131008","journal-title":"Lancet Oncol"},{"issue":"4","key":"7523_CR62","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","volume":"18","author":"R Ladenstein","year":"2017","unstructured":"Ladenstein R, P\u00f6tschger U, Pearson ADJ, Brock P, Luksch R, Castel V et al (2017) Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol 18(4):500\u2013514","journal-title":"Lancet Oncol"},{"issue":"8","key":"7523_CR63","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jama.2019.11642","volume":"322","author":"JR Park","year":"2019","unstructured":"Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD et al (2019) Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA 322(8):746\u2013755","journal-title":"JAMA"},{"issue":"2","key":"7523_CR64","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/sj.bmt.1705929","volume":"41","author":"JD Fish","year":"2008","unstructured":"Fish JD, Grupp SA (2008) Stem cell transplantation for neuroblastoma. Bone Marrow Transplant 41(2):159\u2013165","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"7523_CR65","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2967\/jnumed.122.264775","volume":"64","author":"I Maric","year":"2023","unstructured":"Maric I, Weber M, Prochnow A, Schmitz J, Unger N, Schaarschmidt BM et al (2023) Efficacy and safety of (124)I-MIBG dosimetry-guided high-activity (131)I-MIBG therapy of advanced pheochromocytoma or neuroblastoma. J Nucl Med 64(6):885\u2013891","journal-title":"J Nucl Med"},{"key":"7523_CR66","doi-asserted-by":"crossref","unstructured":"Hjornevik T, Martinsen AC, Hagve SE, Andersen MW, M\u00f8rk AC, Fjeld JG et al (2015) Experiences from introducing standardized high dose 131I-mIBG treatment of children with refractory neuroblastoma: differences in effective dose to patients and exposure to caregivers","DOI":"10.4172\/2155-9619.1000258"},{"issue":"2","key":"7523_CR67","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.21037\/qims-21-548","volume":"12","author":"B Cassano","year":"2022","unstructured":"Cassano B, Pizzoferro M, Valeri S, Polito C, Donatiello S, Altini C et al (2022) Personalized dosimetry for a deeper understanding of metastatic response to high activity (131)I-mIBG therapy in high risk relapsed refractory neuroblastoma. Quant Imaging Med Surg 12(2):1299\u2013310","journal-title":"Quant Imaging Med Surg"},{"issue":"Suppl 1(Suppl 1","key":"7523_CR68","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.nucmedbio.2008.05.002","volume":"35","author":"SG DuBois","year":"2008","unstructured":"DuBois SG, Matthay KK (2008) Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 35(Suppl 1(Suppl 1)):S35-48","journal-title":"Nucl Med Biol"},{"issue":"Supplement_1","key":"7523_CR69","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa046.1293","volume":"4","author":"JG Villablanca","year":"2020","unstructured":"Villablanca JG, Maris JM, Stambler N, Zhou D, DiPippo VA, Matthay KK (2020) SAT-163 status at 10 years: long-term follow-up for a phase 2a study of high-specific-activity (HSA) I 131 iobenguane in patients (Pts) with relapsed\/refractory high-risk neuroblastoma. J Endocr Soc 4(Supplement_1):SAT-163","journal-title":"J Endocr Soc"},{"issue":"1","key":"7523_CR70","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/189135","volume":"2015","author":"D Kayano","year":"2015","unstructured":"Kayano D, Kinuya S (2015) Iodine-131 metaiodobenzylguanidine therapy for neuroblastoma: reports so far and future perspective. Sci World J 2015(1):189135","journal-title":"Sci World J"},{"key":"7523_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/children10121936","author":"HJ Park","year":"2023","unstructured":"Park HJ, Choi JY, Kim BK, Hong KT, Kim HY, Kim IH et al (2023) The impact of (131)I-metaiodobenzylguanidine as a conditioning regimen of tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. Children (Basel). https:\/\/doi.org\/10.3390\/children10121936","journal-title":"Children (Basel)"},{"key":"7523_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205170","author":"S Mastrangelo","year":"2022","unstructured":"Mastrangelo S, Attin\u00e0 G, Zagaria L, Romano A, Ruggiero A (2022) Induction regimen in high-risk neuroblastoma: a pilot study of highly effective continuous exposure of tumor cells to radio-chemotherapy sequence for 1 month. The critical role of Iodine-131-Metaiodobenzylguanidine. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14205170","journal-title":"Cancers (Basel)"},{"key":"7523_CR73","unstructured":"(NCCN) NCCN (2025) NCCN guidelines for neuroblastoma\u00a0"},{"issue":"9","key":"7523_CR74","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1200\/JCO.2006.09.3484","volume":"25","author":"KK Matthay","year":"2007","unstructured":"Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC et al (2007) Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 25(9):1054\u20131060","journal-title":"J Clin Oncol"},{"key":"7523_CR75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02612","author":"T Cash","year":"2025","unstructured":"Cash T, Marachelian A, DuBois SG, Chi Y-Y, Baregamyan A, Groshen SG et al (2025) Phase I study of 131I-metaiodobenzylguanidine with dinutuximab\u00b1vorinostat for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO-24-02612","journal-title":"J Clin Oncol"},{"issue":"10","key":"7523_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29117","volume":"68","author":"BD Weiss","year":"2021","unstructured":"Weiss BD, Yanik G, Naranjo A, Zhang FF, Fitzgerald W, Shulkin BL et al (2021) A safety and feasibility trial of 131I-MIBG in newly diagnosed high-risk neuroblastoma: a Children\u2019s Oncology Group study. Pediatr Blood Cancer 68(10):e29117","journal-title":"Pediatr Blood Cancer"},{"key":"7523_CR77","doi-asserted-by":"crossref","unstructured":"DuBois SG, Allen MS, Bent M, Hilton J, Hollinger F, Courtier J et al (2014) Phase II study of 131I-MIBG with vincristine and 5 days of irinotecan for patients with relapsed or refractory neuroblastoma. American Society of Clinical Oncology\u00a0","DOI":"10.1200\/jco.2014.32.15_suppl.10033"},{"issue":"2","key":"7523_CR78","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13658","volume":"24","author":"JK Suh","year":"2020","unstructured":"Suh JK, Koh KN, Min SY, Kim YS, Kim H, Im HJ et al (2020) Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with 131I-MIBG therapy for high-risk neuroblastoma. Pediatr Transplant 24(2):e13658","journal-title":"Pediatr Transplant"},{"issue":"1","key":"7523_CR79","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.1998.16.1.229","volume":"16","author":"KK Matthay","year":"1998","unstructured":"Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A et al (1998) Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 16(1):229\u2013236","journal-title":"J Clin Oncol"},{"issue":"1","key":"7523_CR80","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-017-0477-0","volume":"10","author":"JW Lee","year":"2017","unstructured":"Lee JW, Lee S, Cho HW, Ma Y, Yoo KH, Sung KW et al (2017) Incorporation of high-dose (131)I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study. J Hematol Oncol 10(1):108","journal-title":"J Hematol Oncol"},{"issue":"1","key":"7523_CR81","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/mpo.1261","volume":"38","author":"B Brans","year":"2002","unstructured":"Brans B, Monsieurs M, Laureys G, Kaufman J-M, Thierens H, Dierckx RA (2002) Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking. Med Pediatr Oncol 38(1):41\u201346","journal-title":"Med Pediatr Oncol"},{"issue":"6","key":"7523_CR82","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2967\/jnumed.122.264775","volume":"64","author":"I Maric","year":"2023","unstructured":"Maric I, Weber M, Prochnow A, Schmitz J, Unger N, Schaarschmidt BM et al (2023) Efficacy and safety of 124I-MIBG dosimetry-guided high-activity 131I-MIBG therapy of advanced pheochromocytoma or neuroblastoma. Journal of nuclear medicine\u202f: official publication, Society of Nuclear Medicine 64(6):885\u2013891","journal-title":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine"},{"key":"7523_CR83","unstructured":"Group CsO (2026) Testing the addition of 131I-MIBG or lorlatinib to intensive therapy in people with high-risk neuroblastoma (NBL) Bethesda, MD: U.S. National Library of Medicine. [Available from: https:\/\/clinicaltrials.gov\/study\/NCT03126916\u00a0"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07523-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-07523-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07523-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:02:55Z","timestamp":1792468975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-07523-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":83,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["7523"],"URL":"https:\/\/doi.org\/10.1007\/s00431-026-07523-z","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"21 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethics Committee of Tehran University of Medical Sciences, Children\u2019s Medical Center (Approval ID: IR.TUMS.CHMC.REC.1404.106).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AI was used for language refinement during manuscript preparation.","order":2,"name":"Ethics","label":"Using AI tools","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"864"}}